Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease

[1] Weissleder R(1990)Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging Radiology 175 489-493

[2] Elizondo G(2018)Relaxivity of Ferumoxytol at 1.5 T and 3.0 T Invest Radiol 53 257-263

[3] Wittenberg J(2009)Physicochemical properties of ferumoxytol, a new intravenous iron preparation Eur J Clin Invest 39 489-496

[4] Rabito CA(2012)USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure Radiology 265 584-590

[5] Bengele HH(2016)MR angiography of renal transplant vasculature with ferumoxytol:: comparison of high-resolution steady-state and first-pass acquisitions Acad Radiol 23 368-373

[6] Josephson L(2013)Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent Transplantation 96 91-96

[7] Knobloch G(2017)Comparison of ferumoxytol-enhanced MRA with conventional angiography for assessment of severity of transplant renal artery stenosis J Magn Reson Imaging 45 779-785

[8] Colgan T(2014)Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases J Magn Reson Imaging 40 113-118

[9] Wiens CN(2015)High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort Pediatr Nephrol 30 515-521

[10] Balakrishnan VS(2016)Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol Pediatr Radiol 46 1332-1340

[1] Weissleder R(1990)Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging Radiology 175 489-493

[2] Elizondo G(2018)Relaxivity of Ferumoxytol at 1.5 T and 3.0 T Invest Radiol 53 257-263

[3] Wittenberg J(2009)Physicochemical properties of ferumoxytol, a new intravenous iron preparation Eur J Clin Invest 39 489-496

[4] Rabito CA(2012)USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure Radiology 265 584-590

[5] Bengele HH(2016)MR angiography of renal transplant vasculature with ferumoxytol:: comparison of high-resolution steady-state and first-pass acquisitions Acad Radiol 23 368-373

[6] Josephson L(2013)Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent Transplantation 96 91-96

[7] Knobloch G(2017)Comparison of ferumoxytol-enhanced MRA with conventional angiography for assessment of severity of transplant renal artery stenosis J Magn Reson Imaging 45 779-785

[8] Colgan T(2014)Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases J Magn Reson Imaging 40 113-118

[9] Wiens CN(2015)High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort Pediatr Nephrol 30 515-521

[10] Balakrishnan VS(2016)Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol Pediatr Radiol 46 1332-1340